Loading...

Sangamo Therapeutics, Inc.

GBY.DEXETRA
Healthcare
Biotechnology
5.05
-0.20(-3.81%)

Sangamo Therapeutics, Inc. (GBY.DE) Stock Competitors & Peer Comparison

See (GBY.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
GBY.DE€5.05-3.81%884.7M-4.38-€1.15N/A
NOV.DE€44.39-6.59%206.2B14.00€3.14+3.47%
VX1.DE€411.15+1.58%105.6B-126.12-€3.26N/A
DUL.DE€227.20+0.00%27.3B-31.91-€7.12N/A
22UA.F€96.45+0.00%23.2B-30.24-€3.19N/A
BM8.DE€61.96-1.71%11.8B88.51€0.70N/A
0QF.F€28.39+2.45%10.9B-3.81-€7.42N/A
EX9.DE€32.28+1.22%9.2B35.47€0.91N/A
MOR.DE€67.25-0.66%2.5B-12.16-€5.53N/A
BBZA.DE€34.60+2.06%1.9B-4.16-€8.31+5.44%
Showing 1 to 10 of 34 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

GBY.DE vs NOV.DE Comparison July 2025

GBY.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBY.DE stands at 884.7M. In comparison, NOV.DE has a market cap of 206.2B. Regarding current trading prices, GBY.DE is priced at €5.05, while NOV.DE trades at €44.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBY.DE currently has a P/E ratio of -4.38, whereas NOV.DE's P/E ratio is 14.00. In terms of profitability, GBY.DE's ROE is -2.75%, compared to NOV.DE's ROE of +0.81%. Regarding short-term risk, GBY.DE is less volatile compared to NOV.DE. This indicates potentially lower risk in terms of short-term price fluctuations for GBY.DE.Check NOV.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;